CME in Minutes: Education in Rheumatology, Immunology, & Infectious Diseases

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.

Please visit answersincme.com/SFM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in family and emergency medicine discuss collaborative strategies for the optimal management of type 2 inflammatory diseases. Upon completion of this activity, participants should be better able to: Specify how type 2 inflammation contributes to the pathophysiology of chronic type 2 inflammatory diseases; Recognize the cardinal signs and symptoms of diseases presenting with type 2 inflammation; Apply treatment considerations for patients with multiple type 2 inflammatory diseases; and Outline strategies for optimizing care coordination for patients with type 2 comorbidities across providers and settings.

Please visit answersincme.com/TSJ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses systemic therapy, including biologics, for the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review recommended management strategies for moderate to severe asthma; Explain the rationale for the use of biologics in the treatment of patients with moderate to severe asthma; Identify patients eligible for systemic therapy for the treatment of moderate to severe asthma; and Outline evidence-based, long-term strategies to improve lung function in patients with moderate to severe asthma.

Please visit answersincme.com/JUC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in obstetrics and gynecology and a cervical cancer survivor discuss strategies to increase human papillomavirus vaccination uptake, thereby reducing cervical cancer risk. Upon completion of this activity, participants should be better able to: Review guideline-recommended clinical strategies to reduce cervical cancer risk; Outline patient-focused strategies to increase acceptance of HPV vaccination across patient subpopulations; and Identify clinical approaches to enhance the uptake of recommended schedules for HPV vaccination.

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VNG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in reproductive health discusses the rationale for human papillomavirus (HPV) vaccination in appropriate adults, its clinical impact, and strategies to incorporate HPV vaccination into prevention plans. Upon completion of this activity, participants should be better able to: Recognize the rationale for HPV vaccination in appropriate adults ages 27-45 years old; Review the clinical impact of HPV vaccination in appropriate adults ages 27-45 years old; and Outline patient-centered strategies to appropriately incorporate HPV vaccination into prevention plans for eligible adults ages 27-45 years old.

Please visit answersincme.com/YZW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses biologic therapy for prurigo nodularis, and a patient presents her perspective. Upon completion of this activity, participants should be better able to: Identify the therapeutic needs of patients with PN; Review the evidence for current and emerging biologic treatments for PN; and Outline how to integrate biologic therapies into the care of patients with PN.

Please visit answersincme.com/UNV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology, immunology, and rheumatology discuss the management of psoriatic arthritis with novel targeted therapies. Upon completion of this activity, participants should be better able to: Recognize the rationale for novel TYK2 inhibitors in the treatment of psoriatic arthritis; Describe the latest clinical data informing the role of TYK2 inhibitors in the treatment of psoriatic arthritis; and Outline future management considerations for novel TYK2 inhibitors in the treatment of psoriatic arthritis.

Please visit answersincme.com/CZY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in pediatric asthma discuss early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Identify the role of early intervention with biologics on the long-term lung function of pediatric patients with moderate to severe asthma; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate to severe asthma on lung function; and Describe evidence-based strategies for optimizing long-term lung function in pediatric patients with moderate to severe asthma. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/WMY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. Upon completion of this activity, participants should be better able to: Define “clinical remission” of asthma; and Review the impact of approved biologics for the treatment of patients with T2 asthma on clinical remission; Outline strategies for incorporating biologics into treatment plans of patients with T2 asthma, with the goal of clinical remission. This activity is intended for US healthcare professionals only.

Please visit answersincme.com/NVY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics and immunology discusses the continued burden of respiratory syncytial virus (RSV) in infants and strategies to increase vaccine uptake. Upon completion of this activity, participants should be better able to: Recognize the rationale for respiratory syncytial virus (RSV) prevention in infants; Review the clinical profiles of national guideline-recommended RSV prophylactic agents in infants; and Outline patient-centered strategies to optimize the uptake of RSV prophylactic options in infants.

Please visit answersincme.com/YFE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in radiation oncology discusses populations at high risk for cervical cancer and how to apply clinical advances and evolve care in locally advanced disease. Upon completion of this activity, participants should be better able to: Identify populations at high risk of developing cervical cancer; Describe strategies to improve uptake of routine screening for cervical cancer, particularly in high-risk populations; and Outline clinical advances that may evolve the care of patients with newly diagnosed high-risk locally advanced cervical cancer.

Please visit answersincme.com/XGU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert dermatologist—who is also an early adopter of generative artificial intelligence (AI)—discusses capabilities and potential applications of generative AI in healthcare, both for clinicians and patients. Upon completion of this activity, participants should be better able to: Describe how generative AI is impacting the practice of medicine both from the clinicians' and patients' perspectives; and Assess the potential benefits and risks of using generative AI in medical practice.

Please visit answersincme.com/XXZ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses human papillomavirus (HPV) vaccination in males to reduce the burden of HPV-related cancers. Upon completion of this activity, participants should be better able to: Recognize the rationale for vaccination against HPV infection in the male population; Describe the clinical evidence for the guideline-recommended HPV vaccines; and Outline strategies to enhance acceptance of HPV vaccination among the male population.

Please visit answersincme.com/GHX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in women's health discusses improving human papillomavirus (HPV) vaccination uptake among lesbian, gay, bisexual, transgender, and queer (LGBTQ+) individuals. Upon completion of this activity, participants should be better able to: Identify the clinical impact of low uptake of HPV vaccination among LGBTQ+ individuals; Review the clinical profiles and suggested administration of guideline-recommended HPV vaccines; and Outline patient-centered strategies to enhance acceptance of HPV vaccination among LGBTQ+ individuals.

Please visit answersincme.com/NRW860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematology-oncology discusses the optimization of care for patients with relapsed/refractory follicular lymphoma (R/R FL) and treatment with bispecific antibodies (BsAbs). Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for using BsAbs in patients with R/R FL; Review the clinical profiles of novel anti-CD20 × CD3 BsAbs for R/R FL; and Describe patient-centered strategies to manage BsAb-associated adverse events in R/R FL.

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.

Please visit answersincme.com/TXC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses the unmet therapeutic needs in patients with chronic obstructive pulmonary disease (COPD) and the rationale for targeting Type 2 inflammation. Upon completion of this activity, participants should be better able to: Recognize the unmet therapeutic needs in patients with COPD; Identify patients with COPD who are at high risk of exacerbations despite receiving standard therapies; and Recognize the rationale for targeting Type 2 inflammation for the treatment of COPD.

Please visit answersincme.com/NQF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses current guideline-supported best practices in the management of moderate to severe asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids (OCS) in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/RYY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy/immunology discusses treatment intensification for adult and pediatric patients with uncontrolled asthma. Upon completion of this activity, participants should be better able to: Review current guideline recommendations regarding the use of oral corticosteroids in patients with moderate to severe asthma; Recognize the latest clinical data concerning the use of biologics in patients with moderate to severe asthma on oral corticosteroids; and Outline patient-centered, practical strategies to enhance the long-term care of patients with moderate to severe asthma.

Please visit answersincme.com/SRG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in dermatology discuss the diagnosis and treatment of prurigo nodularis. Upon completion of this activity, participants should be better able to: Recognize the need for treatment intensification in patients with prurigo nodularis (PN), including patients of color, using novel biologic therapies; Review the clinical profiles of novel biologic therapies for PN; and Outline clinical factors that may facilitate the optimal use of biologic therapies in patients with PN.

Please visit answersincme.com/GQB860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in hematology-oncology discuss B-cell maturation antigen (BCMA)–targeted therapies in the treatment of relapsed/refractory multiple myeloma. Upon completion of this activity, participants should be better able to: Identify where BCMA-targeted therapies fit into the current treatment paradigm of RRMM; Describe the clinical profiles of new and emerging BCMA-targeted bispecific antibodies in heavily treated RRMM; and Outline strategies to optimally incorporate novel BCMA-targeted bispecific antibodies into the treatment paradigm of RRMM.

Please visit answersincme.com/UPM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in allergy and respiratory disease discuss patient-centered strategies to improve treatment of children with asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Please visit answersincme.com/YXX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatrics discusses respiratory syncytial virus (RSV) vaccines for infants. Upon completion of this activity, participants should be better able to: Recognize the rationale for considering respiratory syncytial virus (RSV) vaccines for infants; Describe the clinical profiles of emerging long-acting monoclonal antibodies and maternal vaccines for preventing RSV in infants; and Outline strategies for optimal integration of emerging agents, including overcoming barriers to vaccination, for improving patient outcomes.

Please visit answersincme.com/HQX860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of eosinophilic esophagitis (EoE) discuss biologic therapies targeting type 2 inflammation. Upon completion of this activity, participants should be better able to: Identify the role of type 2 inflammation in EoE in the context of treatment implications; and Describe evidence-based strategies to integrate biologics targeting type 2 inflammation into clinical practice for the management of EoE.

Please visit answersincme.com/EXY860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses the disease severity assessment and treatment of patients with moderately to severely active ulcerative colitis (UC).Upon completion of this activity, participants should be better able to: Identify appropriate strategies to effectively assess disease severity in ulcerative colitis; Describe the rationale for Janus kinase (JAK) inhibitors in targeting the disease pathophysiology in patients with ulcerative colitis; and Outline strategies to individualize the treatment selection for patients with ulcerative colitis.

Please visit answersincme.com/CTR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary infections and vaccination discusses the rationale for respiratory syncytial virus (RSV) vaccination in older adults and how late-stage emerging vaccines can lower their risk of RSV infection. Upon completion of this activity, participants should be better able to: Recognize the burden of disease associated with RSV in older adults; Describe the clinical rationale for vaccines to prevent RSV in older adults; and Evaluate the latest clinical data for late-stage investigational RSV vaccines in older adults.

Please visit answersincme.com/DMC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in infectious disease discuss the clinical impact of mRNA-based COVID-19 vaccines. Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available mRNA-based COVID-19 vaccines; Evaluate the clinical impact of available mRNA-based COVID-19 vaccines; and Apply region-specific, patient-centered strategies to optimize uptake of mRNA-based COVID-19 vaccination.

Please visit answersincme.com/BZR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric infectious diseases discusses prevention of congenital cytomegalovirus (cCMV). Upon completion of this activity, participants should be better able to: Recognize the disease burden of congenital cytomegalovirus; Describe the rationale for novel vaccines in preventing congenital cytomegalovirus; and Outline evidence-based strategies to improve neonatal outcomes in congenital cytomegalovirus.

Please visit answersincme.com/FVG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical impact of novel and emerging tyrosine kinase 2 (TYK2) inhibitors in the treatment of patients with plaque psoriasis who are candidates for systemic therapy. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs for patients with plaque psoriasis who are candidates for systemic therapy; Describe the clinical impact of novel and emerging TYK2 inhibitors in the treatment of eligible patients with plaque psoriasis; and Outline strategies to optimize outcomes for patients with plaque psoriasis who may be candidates for systemic treatment with a TYK2 inhibitor.

Please visit answersincme.com/QWR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the evidence for and appropriate use of newly approved and emerging biologic therapies for the treatment of prurigo nodularis (PN). Upon completion of this activity, participants should be better able to: Recognize the rationale for investigating biologic therapies to address unmet therapeutic needs for patients with PN; Describe the clinical profiles of approved and emerging biologic therapies for the treatment of PN; and Outline approaches to optimally integrate biologic therapies into treatment plans for PN.

Please visit answersincme.com/WBE860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy and immunology discusses how new and emerging therapeutic options targeting type 2 inflammation can improve quality of life for patients with eosinophilic esophagitis (EoE). Upon completion of this activity, participants should be better able to: Recognize the therapeutic rationale for targeting type 2 inflammatory factors to treat EoE; and Outline individual approaches to optimize therapeutic regimens for patients with EoE.

Please visit answersincme.com/DRN860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in gastroenterology discusses emerging small molecule therapies in the treatment of moderate-to-severe Crohn's disease. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using emerging selective Janus kinase (JAK) inhibitors and sphingosine 1–phosphate (S1P) receptor modulators in Crohn's disease; Describe evidence from late-stage clinical trials on the use of small molecule therapies in individuals with moderate-to-severe Crohn's disease; and Outline patient-centered strategies for optimizing treatment with small molecule therapies in moderate-to-severe Crohn's disease.

Please visit answersincme.com/CUA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rheumatology discusses treatment options for non-radiographic axial spondyloarthritis (nr-axSpA). Upon completion of this activity, participants should be better able to: Recognize guideline-recommended treatment options used to reduce the burden of non-radiographic axial spondyloarthritis (nr-axSpA) on patients; Describe the clinical impact of approved and late-stage emerging agents for the treatment of nr-axSpA; and Outline clinical considerations for the role of approved and late-stage emerging agents in the treatment landscape of nr-axSpA.

Please visit answersincme.com/FKQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Dr. Anne O'Donnell, an expert in pulmonology, discusses the role of diagnostic imaging in the diagnosis of non–cystic fibrosis bronchiectasis (NCFB). Upon completion of this activity, participants should be better able to: Recognize the clinical impact of early diagnosis of non–cystic fibrosis bronchiectasis (NCFB); Identify NCFB based on diagnostic imaging; and Describe the clinical profiles of novel and emerging neutrophil-targeted therapies for NCFB.

Please visit answersincme.com/YWV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonology discusses treatment of children with uncontrolled asthma using biologic therapies. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment intensification with a biologic; Review the clinical profiles of current biologics used in the management of moderate-to-severe asthma in children; and Outline evidence-based strategies to optimize outcomes for pediatric patients with moderate-to-severe asthma who require biologics.

Please visit answersincme.com/BWT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses how to identify children with uncontrolled asthma who could benefit from an add-on biologic. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from treatment with add-on biologic therapy; Review the clinical impact of biologics approved for the treatment of pediatric patients with moderate-to-severe asthma; and Outline patient-centered strategies to enhance outcomes for pediatric patients with inadequately controlled moderate-to-severe asthma.

Please visit answersincme.com/DUR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an allergist and immunologist discusses individualized treatment for children with moderate-to-severe asthma. Upon completion of this activity, participants should be better able to: Identify pediatric patients with inadequately controlled moderate-to-severe asthma who may benefit from add-on biologic therapy; Describe the clinical profiles of available biologics for the management of inadequately controlled moderate-to-severe asthma in pediatric patients; and Outline strategies to provide individualized, evidence-based treatment for inadequately controlled moderate-to-severe asthma in pediatric patients.

Please visit answersincme.com/GZT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the latest data in systemic treatments for children with moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Recognize the rationale for treatment intensification with novel systemic agents when managing children with moderate-to-severe atopic dermatitis (AD); Review the latest clinical data informing the current and future use of novel systemic agents in children with moderate-to-severe AD; and Identify opportunities for shared decision-making to improve the care of children with moderate-to-severe AD.

Please visit answersincme.com/JUK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in immunology discusses the burden of respiratory syncytial virus (RSV) in older adults and the clinical impact of late-stage emerging RSV vaccines. Upon completion of this activity, participants should be better able to: Recognize the clinical rationale for vaccines to prevent respiratory syncytial virus (RSV) in older adults; Identify factors contributing to poor RSV outcomes in older adults; and Describe the clinical significance of available data for late-stage investigational RSV vaccines in older adults.

Please visit answersincme.com/KAG860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert on immunization discusses the mechanisms of COVID-19 vaccines, the clinical impact of viral vector–based vaccines and how to improve communication with patients regarding vaccine uptake.Upon completion of this activity, participants should be better able to: Recognize the mechanism of action of available COVID-19 vaccines; Evaluate the clinical impact of available viral vector–based COVID-19 vaccines; and Apply patient-centered counseling strategies to enhance communication with patients to improve COVID-19 vaccine acceptance.

Please visit answersincme.com/TAC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in infectious diseases discusses the early identification and treatment of patients with COVID-19 who are at a higher risk of progression to severe illness. Upon completion of this activity, participants should be better able to: Identify nonhospitalized patients with COVID-19 who have risk factors for progression to severe illness; Describe national guideline recommendations for the therapeutic management of nonhospitalized patients with COVID-19 who are at risk for progression to severe illness; and Outline a personalized management approach to enhance outcomes for nonhospitalized patients who are diagnosed with COVID-19 and are at risk for progression to severe illness.